TPST (Tempest Therapeutics) Forward P/E Multiple
The forward P/E ratio for Tempest Therapeutics (TPST) demonstrates a price corridor where the 0.00 mark characterizes this parameter. Cancer therapy risks are extreme due to pressure from resource behemoths. Geopolitics complicates cross-border cooperation and the patent protection of technologies. The success of Tempest Therapeutics is based on clinical data that determine its position in the high-margin targeted drug segment.
Summary analytical data breakdowns for Tempest Therapeutics Corp (TPST)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Tempest Therapeutics|TPST - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Tempest Therapeutics|TPST - Company Cumulative Indebtedness|Debts to Book Capitalization Tempest Therapeutics Inc|TPST - Long-Term Debt|Company Short-Term Debt Tempest Therapeutics|Quick Liquidity tempesttx.com
- financial results and valuation multiples details:
TPST - Profit After Tax|Projected Future Earnings Tempest Therapeutics|TPST - Market Cap to Earnings|Future Price to Earnings Tempest Tx|TPST - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Tempest Therapeutics Inc|TPST - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Tempest Therapeutics|TPST - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months tempesttx.com|TPST - Net earnings per one share growth for the current year|Earnings growth forecast for next year Tempest Therapeutics
Summary company analysis:Tempest Therapeutics, Inc.
Forward P/E measures the market value of every dollar of expected earnings, allowing an investor to assess the extent of the premium paid for future financial results based on current guidance. Analyzing the forward P/E multiple for Tempest Therapeutics (TPST) reveals how the exclusivity of patents for anti-cancer compounds and high FDA barriers protect future cash flows from competition, justifying the current capitalization.
Competitors of Tempest Therapeutics (TPST)
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Projected Price to Earnings YMAB (Y-mAbs Therapeutics)|Market Cap to Future Earnings Ratio AURA|Forward P/E Multiple CADL (Candel Therapeutics, Inc.)|Accuray Inc (ARAY) - Projected Price to Earnings Ratio|SLS - Future Price to Earnings|Actuate Therapeutics Inc (ACTU) - Projected Price to Earnings|Citius Oncology, Inc. (CTOR) - Future Price to Earnings|Price to Expected Earnings Ratio HURA (TuHURA Biosciences)|TARA (Protara Therapeutics, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio Fate Therapeutics Inc FATE|Future Price to Earnings Aadi Bioscience Inc (WHWK)|Market Cap to Projected Earnings tscan.com|Champions Oncology, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio XBIT (XBiotech Inc)|CVM: Projected Price to Earnings|Future Price to Earnings Multiple OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Projected Price to Earnings|ARTV: Market Cap to Future Earnings Ratio|ANL (Adlai Nortye Ltd) - Forward P/E Multiple|VERU: Future Price to Earnings Multiple|Forward P/E Multiple XLO|RENB - Projected Price to Earnings Ratio|Future Price to Earnings Mural Oncology MURA|Future Price to Earnings Multiple KAPA|OnKure - Forward P/E Multiple|GDTC - Forward P/E Multiple|curis.com (CRIS) - Future Price to Earnings|Price to Expected Earnings Ratio APLM (Apollomics)|THAR (Tharimmune Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Advanced Biomed Corp ADVB|Projected Price to Earnings GNPX (Genprex, Inc.)|Forward P/E Multiple calidibio.com (CLDI)|Sunshine Biopharma, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio XBIO (Xenetic Biosciences Inc.)|Salarius - Forward P/E Multiple|Market Cap to Projected Earnings Kitov Pharma PPBT|AONC: Forward P/E Multiple|Projected Price to Earnings beigene.com|Future Price to Earnings Checkpoint Therapeutics, Inc.|elevationoncology.com (ELEV) - Market Cap to Projected Earnings|Projected Price to Earnings ICAD (iCAD, Inc.)|Market Cap to Future Earnings Ratio IKNA|Future Price to Earnings Notable Labs, Ltd. NTBL|VIRX (Viracta Therapeutics Inc.) - Price to Expected Earnings Ratio|MOR - Future Price to Earnings|Market Cap to Projected Earnings NAYA Biosciences Inc NAYA|AAPGV (Ascentage Pharma Group Ltd) - Projected Price to Earnings
